ARACLON BIOTECH, the Spanish biotechnology company,
recently presented results endorsing the capacity for diagnosis of the early

• This is an international congress for the
  pharmaceutical and biotechnological industry, held in San Francisco in
  September and in which the Spanish biotechnology has, for the first time,
  its own stand.

Throughout 2009 the vaccine will start regulatory pre-clinical development and Araclon Biotech expects to start clinical trials on humans at the end of the coming year.

This is the first European Patent for the biotechnology company Araclon Biotech, and one of the few awarded each year to Spanish companies in the sector.